Purple Biotech Reports Positive Phase 2 Data for Candida
Ticker: PPBT · Form: 6-K · Filed: Sep 18, 2024 · CIK: 1614744
Sentiment: neutral
Topics: clinical-trial-data, oncology, phase-2
TL;DR
Purple Biotech's lead cancer drug shows good interim results in Phase 2 trial.
AI Summary
On September 18, 2024, Purple Biotech Ltd. announced additional positive interim data from its Phase 2 study of its oncology therapeutic, Candida. The study is a randomized trial evaluating the efficacy and safety of Candida in patients with advanced unresectable hepatocellular carcinoma (HCC). The company did not disclose specific numerical data or dollar amounts in this filing.
Why It Matters
Positive interim data from a Phase 2 study can significantly impact a company's stock price and future development plans, potentially moving it closer to late-stage trials and regulatory approval.
Risk Assessment
Risk Level: medium — The filing reports positive interim data, which is encouraging, but the full study results and regulatory path are still uncertain.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- Candida (drug) — Lead oncology therapeutic
- September 18, 2024 (date) — Date of press release
- 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel (address) — Principal executive offices
FAQ
What specific positive interim data was reported for the Phase 2 study of Candida?
The filing states that additional positive interim data was reported, but does not specify the exact nature or numerical results of this data.
What is the indication for Purple Biotech's lead oncology therapeutic, Candida?
Candida is being evaluated for patients with advanced unresectable hepatocellular carcinoma (HCC).
What type of study is being conducted for Candida?
It is a randomized Phase 2 study.
When was this press release issued?
The press release was issued on September 18, 2024.
What is Purple Biotech Ltd.'s principal executive office address?
The principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-09-18 06:32:13
Filing Documents
- ea0214959-6k_purple.htm (6-K) — 15KB
- ea021495901ex99-1_purple.htm (EX-99.1) — 21KB
- 0001213900-24-079613.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. September 18, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2